Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) announced inducement awards under Nasdaq Listing Rule 5635(c)(4) granted to six new non-executive employees on April 29, 2026. The grants comprise a total of 122,400 RSUs across the recipients, with vesting in thirds over three or four years and subject to continued service and the 2020 Inducement Incentive Plan.
The Compensation Committee approved the awards as material inducements to employment; vesting schedules vary by grant and are tied to service anniversaries.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – STIM
On the day this news was published, STIM gained 14.12%, reflecting a significant positive market reaction. Argus tracked a peak move of +14.0% during that session. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $17M to the company's valuation, bringing the market cap to $135.66M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
STIM was down 2.96% while peers were mixed: BSGM up 39.91%, CVRX down 7.79%, ELMD down 2.03%, TLSI down 4.27%, BWAY down 0.78%. This points to stock-specific factors rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | Earnings date notice | Neutral | -5.1% | Set date and time to report Q1 2026 results and host call. |
| Apr 13 | Coverage expansion | Positive | +3.0% | Optum/UHC policy change expands NeuroStar TMS access to PMHNPs. |
| Apr 07 | Activist response | Positive | -10.2% | Company responds to major holder letter, stressing commitment to value. |
| Apr 06 | CFO transition | Negative | -10.2% | CFO resignation announcement alongside reaffirmed fiscal 2026 guidance. |
| Apr 06 | Activist letter | Neutral | -10.2% | Largest independent holder urges review of strategic alternatives. |
Recent news has often involved governance, strategic reviews, and leadership changes, with several items followed by double‑digit negative price reactions, while operational positives like coverage expansion saw modest gains.
Over the last month, Neuronetics announced an earnings date on April 21, 2026, expanded NeuroStar TMS coverage to more providers and 26 states, and addressed an activist shareholder letter citing a 14.12% stake and potential strategic alternatives. Leadership transitions, including a CFO resignation and broader cost‑reduction initiatives, coincided with negative price moves. Today’s inducement RSU grants fit into ongoing compensation and governance activity alongside an effective resale shelf for 20,737,061 shares.
Regulatory & Risk Context
An effective S-3 resale shelf dated March 17, 2026 registers up to 20,737,061 common shares for selling stockholders, with the company receiving no proceeds. The filing notes these shares represent a significant portion of outstanding stock and that concurrent sales could affect the market price.
Market Pulse Summary
The stock surged +14.1% in the session following this news. A strong positive reaction aligns with a backdrop of recent activist interest and insider share purchases, while the news itself focuses on inducement RSU awards for new employees under the 2020 Inducement Incentive Plan. With shares trading well below the $2.30 200-day MA and roughly 64.94% under the 52-week high, prior governance and restructuring headlines, plus an effective resale shelf for 20,737,061 shares, would remain important risk factors to monitor.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock units financial
inducement incentive plan financial
AI-generated analysis. Not financial advice.
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.
Restricted stock units (“RSUs”)
| Name | Number of Inducement Plan RSUs | Vesting Schedule |
| Jeffrey Miller | 70,000 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Jeffrey Miller | 35,000 | 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Michael Walsh | 600 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Christina Piacentino | 3,000 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Angelo Gonzalez | 2,400 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Lori Flint | 2,400 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
| Carole Corcoran | 9,000 | 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date. |
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (“MDD”) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
